Sunshine Biopharma
SBFM
9 hedge funds and large institutions have $187K invested in Sunshine Biopharma in 2025 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
50% more funds holding
Funds holding: 6 → 9 (+3)
23% more capital invested
Capital invested by funds: $152K → $187K (+$35.5K)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
0.01% less ownership
Funds ownership: 0.29% → 0.29% (-0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$92.7K |
| 2 |
Renaissance Technologies
New York
|
+$79K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.28K |
| 4 |
SS
SBI Securities
Tokyo,
Japan
|
+$2.15K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$219 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$28.8K |
| 2 |
RA
Rise Advisors
Rochester,
New York
|
-$2 |
SBFM Hedge Fund Activity: Q2 2025 in Review
9 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Sunshine Biopharma (SBFM) for Q2 2025, worth a combined $187K — up 23% from $152K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new SBFM positions and 1 closed out — a net gain of 3 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $92.7K. The largest seller was UBS Group, cutting an estimated $28.8K.
- 9 institutional investors held Sunshine Biopharma (SBFM) as of Q2 2025, up from 6 in Q1 2025.
- Funds reported $187K of Sunshine Biopharma stock for Q2 2025, up 23% quarter-over-quarter.
- 4 funds opened new Sunshine Biopharma positions in Q2 2025 and 1 closed out, a net change of +3 holders.
- The largest Sunshine Biopharma buyer in Q2 2025 was Citadel Advisors, an estimated $92.7K added.
- The largest Sunshine Biopharma seller in Q2 2025 was UBS Group, an estimated $28.8K sold.
Based on aggregated 13F filings for Q2 2025.